Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib

Oncology (Switzerland)

Volumn 92, Issue 6, 2017, Pages 335-346

  Kawaoka, Tomokazu ^a   Aikata, Hiroshi ^a   Teraoka, Yuji ^a   Inagaki, Yuki ^a   Honda, Fumi ^a   Hatooka, Masahiro ^a   Morio, Kei ^a   Morio, Reona ^a   Kobayashi, Tomoki ^a   Nagaoki, Yuko ^a   Nakahara, Takashi ^a   Hiramatsu, Akira ^a   Tsuge, Masataka ^a   Imamura, Michio ^a   Kawakami, Yoshiiku ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Sorafenib; Sustained viral response

Indexed keywords

ASUNAPREVIR; DACLATASVIR; PEGINTERFERON; RIBAVIRIN; SORAFENIB; TELAPREVIR; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIARRHEA; DISEASE CONTROL; DISEASE ERADICATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEPATIC COMA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTRANSAMINASEMIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTPROGRESSION SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL; SUSTAINED VIROLOGIC RESPONSE; TIME TO TREATMENT; TREATMENT RESPONSE; VERY ELDERLY; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; JAPAN; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; TREATMENT OUTCOME; VIROLOGY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 85014107819     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000458532     Document Type: Article

References (25)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
3. Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K: Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol 2011; 46: 799-808.
4. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Pena C, Molnar I, Schlumberger MJ; DECISION investigators: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384: 319-328.
5. Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H: Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. BJU Int 2011; 108: 1813-1819.
6. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E: Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083-2091.
7. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo H, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M: Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015; 15: 645-653.
8. Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, Umemura T, Takehara T, Sakamoto N, Nishigaki Y, Nakane K, Toda N, Ide T, Yanase M, Hino K, Gao B, Garrison KL, Dvory-Sobol H, Ishizaki A, Omote M, Brainard D, Knox S, Symonds WT, McHutchison JG, Yatsuhashi H, Mizokami M: Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an openlabel, phase 3 trial. J Viral Hepat 2014; 21: 762-768.
9. Kumada H, Chayama K, Rodrigues L Jr, Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, Setze C, Pilot-Matias T, Patwardhan M, Vilchez RA, Burroughs M, Redman R: Randomized phase 3 trial of ombitasvir/ paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 2015; 62: 1037-1046.
10. Nagaoki Y, Aikata H, Nakano N, Shinohara F, Nakamura Y, Hatooka M, Morio K, Kan H, Fujino H, Kobayashi T, Fukuhara T, Masaki K, Ono A, Nakahara T, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Kawakami Y, Ochi H, Chayama K; Hiroshima Liver Study Group: Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study. J Gastroenterol Hepatol 2016; 31: 1009-1015.
11. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-232.
12. Edeline J, Boucher E, Rolland Y, Vauleon E, Pracht M, Perrin C, Le Roux C, Raoul JL: Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118: 147-156.
13. The general rules for the clinical and pathological study of primary liver cancer. Liver cancer study group of Japan. Jpn J Surg 1989; 19: 98-129.
14. Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, Kudo M, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M: Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC guidelines). Hepatol Res 2015, DOI: 10. 1111/hepr. 12464.
15. Vitale A, Morales RR, Zanus G, Farinati F, Burra P, Angeli P, Frigo AC, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnu L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F, Cillo U; Italian Liver Cancer Group: Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol 2011; 12: 654-662.
16. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Saito T, Motoyama T, Suzuki E, Tawada A, Kanai F, Yokosuka O: Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs 2015; 33: 729-739.
17. Choi GH, Shim JH, Kim MJ, Ryu MH, Ryoo BY, Kang YK, Shin YM, Kim KM, Lim YS, Lee HC: Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology 2013; 269: 603-611.
18. Schmidt L, op den Winkel M, Fischer K, Straub G, Rauch B, Paprottka PM, Goke B, Kolligs FT: Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C). Digestion 2014; 90: 219-228.
19. Terashima T, Yamashita T, Takata N, Nakagawa H, Toyama T, Arai K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S: Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. Hepatol Res 2016; 46: 650-656.
20. Yoshida K, Hirokawa T, Moriyasu F, Liu L, Liu GJ, Yamada M, Imai Y: Arterial-phase contrast-enhanced ultrasonography for evaluating anti-angiogenesis treatment: a pilot study. World J Gastroenterol 2011; 17: 1045-1050.
21. Hidaka H, Nakazawa T, Kaneko T, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Koizumi W: Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. J Gastroenterol 2012; 47: 1030-1035.
22. Raoul JL, Bruix J, Greten TF, Sherman M, Mazzaferro V, Hilgard P, Scherubl H, Scheulen ME, Germanidis G, Dominguez S, Ricci S, Nadel A, Moscovici M, Voliotis D, Llovet JM: Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: sharp trial subanalyses. J Hepatol 2012; 56: 1080-1088.
23. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, Diaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J: Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65: 719-726.
24. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S: Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65: 727-733.
25. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts): Lack of evidence of an effect of directacting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016; 65: 734-740.